AT
Absco Therapeutics, Inc.
SEC filingBiotechnology · Allston, MA
Amount raised$5Msold at filing
Total offering$5M
Investors in the raise1count reported to the SEC
FiledAug 27, 2025first sale Aug 18, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Stephen LindermanExecutive Officer, Director
Carlo Giovanni TraversoDirector
Avik SomDirector
Executive officers, directors and promoters as listed on the Form D.